Use of polymorphic forms of rifaximin for medical preparations

Details Use of polymorphic forms of rifaximin for medical preparations Use of polymorphic forms of rifaximin for medical preparations

2011-03-29

2011-03-29

Kifle, Bruck (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

07915275

ABSTRACT:
The present invention relates to Rifaximin polymorphic forms α, β and γ, to their use in medicinal preparations for the oral or topical route and to therapeutic methods using them.

REFERENCES:
patent: 4341785 (1982-07-01), Marchi et al.
patent: 4557866 (1985-12-01), Cannata et al.
patent: 7045620 (2006-05-01), Viscomi et al.
patent: 2009/0028940 (2009-01-01), Jahagirdar et al.
patent: 2009/0082558 (2009-03-01), Kothakonda et al.
patent: 2009/0312357 (2009-12-01), Rao et al.
patent: 1215976 (1986-12-01), None
patent: 1218650 (1987-03-01), None
patent: 0 161 534 (1985-11-01), None
patent: 0161534 (1985-11-01), None
patent: 1698630 (2006-09-01), None
patent: 1557421 (2007-05-01), None
patent: 2011486 (2009-01-01), None
patent: MI2005A000345 (2005-03-01), None
patent: 2008/155728 (2008-12-01), None
patent: 2009/008005 (2009-01-01), None
patent: 2009/047801 (2009-04-01), None
European Patent No. 1 557 421, Reply to the Communication pursuant to Article 96(2), May 2, 2006.
European Patent No. 1 557 421, Opposition Proceedings, “Notice of opposition to a European patent,” Feb. 11, 2008.
European Patent No. 1 557 421, Opposition Proceedings, Patentee response to Notice of Opposition, Sep. 10, 2008.
European Patent No. 1 557 421, Opposition Proceedings, Opinion of the Opposition Division, Jan. 19, 2009.
European Patent No. 1 557 421, Opposition Proceedings, Patentee response to summons to attend oral proceedings, Apr. 22, 2009.
European Patent No. 1 557 421, Opposition Proceedings, Opponent response to summons to attend oral proceedings, Apr. 29, 2009.
European Patent No. 1 557 421, Opposition Proceedings, Patentee response to brief communication, May 29, 2009.
European Patent No. 1 557 421, Opposition Proceedings, European Patent Office Decision rejecting the opposition, Jul. 8, 2009.
European Patent No. 1 557 421, Opposition Proceedings, Appellant Notice of Appeal, Sep. 18, 2009.
European Patent No. 1 557 421, Opposition Proceedings, Appellant Statement of Grounds for Appeal, Nov. 18, 2009.
Alvisi, V. et al., “Treatment of Secretory Diarrhoeas—A Double-Blind Trial of the Effectiveness of Rifaximin (L 105) and Neomycin,” Clinical Trials Journal, 1984, 21, No. 4, pp. 215-223.
Rodriguez-Spong, B. et al., “General Principles of Pharmaceutical Solid Polymorphism: a Supramolecular Perspective,” Advanced Drug Delivery Reviews, 56 (2004), 241-274.
Morris, K.R. et al., “Theoretical Approaches to Physical Transformations of Active Pharmaceutical Ingredients During Manufacturing Processes,” Advanced Drug Delivery Reviews, 48 (2001), 91-114.
Viscomi, G.C. et al., “Crystal Forms of Rifaximin and Their Effect on Pharmaceutical Properties,” CrysEngComm, 2008, 10, 1074-1081.
Brufani, M. et al., “X-Ray Crystal Structure of 4-Deoxy-3′-bromopyrido[1′,2′-1,2]imidazo[5,4-c]rifamycin S,” The Journal of Antibiotics, 37:12, 1623-1627 (Dec. 1984).
Soro, O. et al., “Selection of Rifampicin-Resistant Mycobacterium Tuberculosis Does Not Occur in the Presence of Low Concentrations of Rifaximin,” Clin Microbiol Infect, 1997, 3:147-151.
TicinumLab. Example 7, Patent EP 0 161 534, “Synthesis of 4-Deoxy-4′methyl-pyrido-[1′,2′:1,2]imidazo]5,4-c]ryfamicin SV.”
TicinumLab. Example 9, Patent EP 0 161 534, “Synthesis of 4-Deoxy-4′methyl-pyrido-[1′,2′:1,2]imidazo]5,4-c]ryfamicin SV.”
Department of Health and Human Services, Certificate of GMP Compliance of a Manufacturer, Nov. 16, 2007.
European Medicines Industry, ICH Topic Q6A, Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, pp. 1-32, 2000.
Henwood, S.Q. et al., “Solubility and Dissolution Properties of Generic Rifampicin Raw Materials,” Drug Development and Industrial Pharmacy, 26(4), 403-408 (2000).
Morris, K.R. “Polymorphism in Pharmaceutical Solids,” in “Structural Aspects of Hydrates and Sovates,” H.G. Brittain editor, Drugs and the Pharmaceutical Sciences, vol. 95, Chapter 4, pp. 125-181, 1999.
Rifaximin—Intrinsic Dissolution Experimental Data, Apr. 2009.
Bacchi, A. et al., “Sampling Rifamycin Conformational Variety by Cruising Through Crystal Forms: Implications for Polymorph Screening and for Biological Models,” New J. Chem., 2008, 32, 1725-1735.
Venturini, A.P. “Pharmacokinetics of L/105, a New Rifamycin, in Rats and Dogs, after Oral Administration,” Chemotherapy 29:1-3 (1983).
Pelizza, G. “Polymorphism of Rifampicin,” II Farmaco—Ed. Sc., vol. 32, No. 7, pp. 471-481, 1977.
Rao, R.N. et al., “O-Line 2D-LC-ESI/MS/MS Determination of Rifaximin in Rat Serum,” Biomed. Chromatogr. 2009, 1-6.
Descombe, J.J. et al., “Pharmacokinetic Study of Rifaximin After Oral Administration in Healthy Volunteers,” Int. J. Clin. Pharm. Res. XIV(2), 51-56 (1994).
Rossi, C. et al., “NMR Investigation of a New Semisynthetic Bioactive Compound,” Bulletin of Magnetic Resonance, 1996, vol. 18, No. 1-2, pp. 87-90.
Italian Product Label for NORMIX (rifaximin), Apr. 23, 1985.
Cellai, L. et al., “A Study of Structure-Activity Relationships in 4-Deoxypyrido[1′,2′-1,2] imidazo[5,4-c]rifamycin SV Derivatives by Electron Spectroscopy for Chemical Analysis and 1H NMR,” Molecular Pharmacology, 27:103-108, 1984.
European Patent No. 1 557 421, Opposition Proceedings, “Opponent Response to the Late Submissions of Patentee,” Jun. 11, 2009.
European Patent No. 1 557 421, Opposition Proceedings, “Patentee Response to Opponent Statement Setting Out the Grounds of Appeal,” Jun. 2, 2010.
Zach Systems SPA, “Synthesis of rifaximin obtained according to examples 7 and 9 reported in European Patent EP0161534,” May 13, 2010.

Affiliated with

Also associated with

Rating

Use of polymorphic forms of rifaximin for medical preparations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of polymorphic forms of rifaximin for medical preparations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of polymorphic forms of rifaximin for medical preparations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2764158